Home » Stocks » Soleno Therapeutics

Soleno Therapeutics, Inc. (SLNO)

Stock Price: $1.72 USD -0.08 (-4.44%)
Updated Jul 31, 2020 4:00 PM EDT - Market closed
After-hours: $1.68 -0.04 (-2.33%) Jul 31, 6:26 PM

Stock Price Chart

Key Info

Market Cap 136.84M
Revenue (ttm) n/a
Net Income (ttm) -29.60M
Shares Out 79.56M
EPS (ttm) -0.79
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 31, 2020
Last Price $1.72
Previous Close $1.80
Change ($) -0.08
Change (%) -4.44%
Day's Open 1.79
Day's Range 1.67 - 1.80
Day's Volume 605,478
52-Week Range 1.18 - 4.39

More Stats

Market Cap 136.84M
Enterprise Value 122.09M
Earnings Date (est) Aug 6, 2020
Ex-Dividend Date n/a
Shares Outstanding 79.56M
Float 28.22M
EPS (basic) -0.8
EPS (diluted) -0.79
FCF / Share -0.43
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.83M
Short Ratio 1.76
Short % of Float 4.16%
Beta 0.44
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 14.35
Revenue n/a
Operating Income -27.12M
Net Income -29.60M
Free Cash Flow -19.36M
Net Cash 14.76M
Net Cash / Share 0.19
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -47.77%
ROE -178.80%
ROIC 822.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (2)

Buy 2
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$8.50*
(394.19% upside)
Low
8.00
Current: $1.72
High
9.00
Target: 8.50
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013
Revenue----0.61-3.00
Gross Profit----0.25-3.00
Operating Income-23.20-13.73-9.87-8.32-12.16-5.16-0.85
Net Income-30.77-13.34-15.39-12.07-15.91-13.24-3.71
Shares Outstanding34.1420.988.983.101.890.250.11
Earnings Per Share-0.90-0.64-1.71-5.07-8.45-52.10-34.60
Operating Cash Flow-17.38-11.68-9.95-13.50-10.30-4.48-0.89
Capital Expenditures-0.02-0.01--0.01-0.06-0.03-
Free Cash Flow-17.40-11.69-9.95-13.51-10.36-4.52-0.89
Cash & Equivalents20.7324.0817.142.765.537.981.29
Total Debt0.31----0.1013.99
Net Cash / Debt20.4324.0817.142.765.537.88-12.70
Assets38.1743.1539.025.568.208.401.59
Liabilities23.2312.7412.212.134.9819.5939.45
Book Value14.9530.4126.823.443.22-11.19-37.86
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Soleno Therapeutics, Inc.
Country United States
Employees 12
CEO Anish Bhatnagar

Stock Information

Ticker Symbol SLNO
Stock Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Unique Identifier NASDAQ: SLNO
IPO Date November 13, 2014

Description

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.